Literature DB >> 2556943

Relationship of lymph node metastasis to primary tumor size and microscopic appearance of roentgenographically occult lung cancer.

N Nagamoto1, Y Saito, S Ohta, M Sato, K Kanma, M Sagawa, S Takahashi, K Usuda, T Nakada, K Hashimoto.   

Abstract

We investigated the relationship of lymph node metastasis to primary tumor size and microscopic appearance in 92 resected specimens obtained from patients with roentgenographically occult lung cancer (ROLC) located at a site along the airway between the main bronchus and the sub-subsegmental bronchi. Most of the patients were discovered by mass screening. All were treated surgically after bronchoscopic localization of cancer. The bronchial tree of the resected specimens was serial-sectioned into 2-mm thick blocks from the margin of resection to the sub-subsegmental bronchi. Bronchial wall invasion was noted in some blocks of all the specimens. The length of longitudinal extension (LLE) was defined as the product of the thickness and the number of consecutive blocks involved, counting from the most proximal to the most distal block. LLE was used as primary tumor size. Hilar and mediastinal lymph nodes were examined in 84 patients who underwent lymph node dissection. No nodal involvement was found in 59 cancers with LLE of less than 20 mm. Of 25 cancers with LLE of 20 mm or more, six showed nodal involvement. Eleven in situ carcinomas and four cancers of the "suspicious for invasion" type showed no lymph node metastasis. We contend that no lymph node dissection is required when pulmonary resection is performed for patients with ROLC if it is in situ carcinoma, if it is of the "suspicious for invasion" type, or if the LLE is smaller than 20 mm.

Entities:  

Mesh:

Year:  1989        PMID: 2556943     DOI: 10.1097/00000478-198912000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Pulmonary preinvasive neoplasia.

Authors:  K M Kerr
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

Review 2.  Techniques of endoscopic airway tumor treatment.

Authors:  Nicolas Guibert; Laurent Mhanna; Sylvain Droneau; Gavin Plat; Alain Didier; Julien Mazieres; Christophe Hermant
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  The IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view.

Authors:  Wentao Fang; Yangwei Xiang; Chenxi Zhong; Qunhui Chen
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection.

Authors:  Keyvan Moghissi; Kate Dixon; James Andrew Charles Thorpe; Mark Stringer; Christopher Oxtoby
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

Review 5.  Photodynamic therapy.

Authors:  T J Dougherty; C J Gomer; B W Henderson; G Jori; D Kessel; M Korbelik; J Moan; Q Peng
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

6.  VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.

Authors:  Li-Cheng Du; Xian-Cheng Chen; Dong Wang; Yan-Jun Wen; Chun-Ting Wang; Xue-Mei Wang; Bing Kan; Yu-Quan Wei; Xia Zhao
Journal:  Reprod Biol Endocrinol       Date:  2014-02-06       Impact factor: 5.211

7.  VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.

Authors:  Xiaorong Qi; Licheng Du; Xiancheng Chen; Lijuan Chen; Tao Yi; Xiang Chen; Yanjun Wen; Yuquan Wei; Xia Zhao
Journal:  Int J Oncol       Date:  2016-05-17       Impact factor: 5.650

8.  Nodular-type central squamous cell lung carcinoma cured by intraluminal bronchoscopic treatment: A case report.

Authors:  Hikaru Aoki; Keigo Uchimura; Tatsuya Imabayashi; Yuji Matsumoto; Masahiro Higashiyama; Shun-Ichi Watanabe; Takaaki Tsuchida
Journal:  Thorac Cancer       Date:  2021-07-28       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.